Showing Results for
- Academic Journals (7,253)
Search Results
- 7,253
Academic Journals
- 7,253
-
From:Nurse Practitioners' Prescribing Reference (Vol. 21, Issue 1) Peer-ReviewedCompany: Bayer Healthcare| Rx Pharmacologic class: Soluble guanylate cyclase (sGC) stimulator. Active ingredient: Riociguat 0.5mg, 1 mg, 1.5mg, 2mg, 2.5mg; tablets. Indication:...
-
From:MPR - Physician Assistants' Edition (Vol. 21, Issue 1)Company: Bayer Healthcare |Rx Pharmacologic class: Soluble guanylate cyclase (sGC) stimulator. Active ingredient: Riociguat 0.5mg, 1mg, 1.5mg, 2mg, 2.5mg; tablets. Indication: Treatment of persistent/recurrent...
-
From:MPR - Physician Assistants' Edition (Vol. 23, Issue 2)Company: Actelion Pharmaceuticals Rx Pharmacologic class: Prostacyclin receptor agonist Active ingredients: Selexipag 200mcg, 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg; tablets. Indication:...
-
From:MPR - Physician Assistants' Edition (Vol. 20, Issue 4)Opsumit (macitentan; Actelion) tablets have been approved for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression, which includes death, initiation of intravenous or subcutaneous...
-
From:Nurse Practitioners' Prescribing Reference (Vol. 21, Issue 1) Peer-ReviewedCompany: Actelion | Rx Pharmacologic class: Endothelin receptor antagonist. Active ingredient: Macitentan 10mg; tablets. Indication: Treatment of pulmonary arterial hypertension (PAH)...
-
From:MPR - Physician Assistants' Edition (Vol. 20, Issue 4)The FDA has approved Adempas (riociguat; Bayer) tablets for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgery or inoperable CTEPH to improve exercise...
-
From:MPR - Physician Assistants' Edition (Vol. 21, Issue 1)Pharmacologic class: Endothelin receptor antagonist. Active ingredient: Macitentan 10mg; tablets. Indication: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to delay disease progression. In clinical...
-
From:Annals of Thoracic Medicine (Vol. 8, Issue 2) Peer-ReviewedByline: Majdy. Idrees, Enas. Batubara, Tarek. Kashour Sir, Dr. Yalcinkaya [sup][1] pointed out a very important concept for the limitation of 2 dimentional echocardiography (2D) in the assessment of RV function...
-
From:Mayo Clinic Proceedings (Vol. 88, Issue 12) Peer-ReviewedA 69-year-old woman presented to her primary care physician with increasing abdominal distention and a 13-kg unintentional weight loss over 1 year. She also reported new lower extremity edema, mild dyspnea on exertion,...
-
From:Medical Economics (Vol. 90, Issue 24)FDA approved riociguat (Adempas) tablets for the treatment of adults with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH as well as adults with pulmonary arterial...
-
From:Annals of Thoracic Medicine (Vol. 9, Issue 5) Peer-ReviewedByline: Adriano. Tonelli, Omar. Minai Patients with pulmonary hypertension (PH) are being encountered more commonly in the perioperative period and this trend is likely to increase as improvements in the recognition,...
-
From:Annals of Thoracic Medicine (Vol. 9, Issue 5) Peer-ReviewedByline: Qadar. Pasha Pulmonary hypertension (PH) is a phenotype characterized by functional and structural changes in the pulmonary vasculature, leading to increased vascular resistance. [sup][1],[2] The World Health...
-
From:The Egyptian Journal of Cardiothoracic Anesthesia (Vol. 8, Issue 3) Peer-ReviewedByline: Rabie. Soliman, Reda. Atta Context Milrinone is an inodilator commonly used to improve myocardial function and to decrease pulmonary hypertension. Aim The aim of this study was to compare two different...
-
From:Tanta Medical Journal (Vol. 43, Issue 2) Peer-ReviewedByline: Tamer. Elbedewy, Samah. Elshweikh, Amira. Abd El-Naby, Eman. Elsheikh Background/aim Thalassemia constitutes a heterogeneous group of inherited anemia. In Egypt, 1000/1.5 million live births per year suffer...
-
From:Pediatric News (Vol. 49, Issue 8)Between 1997 and 2012, the proportion of hospitalizations in the United States for pediatric pulmonary hypertension doubled, from 1 in 1,000 discharges for the condition in 1997 to 1 in 500 in 2012, a national...
-
From:Obesity, Fitness & Wellness Week2015 OCT 31 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Cardiovascular Diseases and Conditions is now available. According to news reporting originating from...
-
From:Obesity, Fitness & Wellness WeekResearch findings, "Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension," are discussed in a new report. "Remodeling of the pulmonary arteries is a common feature among the...
-
From:PVRI Review (Vol. 4, Issue 1) Peer-ReviewedByline: Pratibha. Nallari, BKS. Sastry Introduction Idiopathic Pulmonary arterial hypertension (IPAH) is a condition characterized by elevated pulmonary artery pressures (>25mmHg), leading to right heart failure...
-
From:Internal Medicine News (Vol. 45, Issue 19)AT THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS ATLANTA--Riociguat, a novel first-in-class guanylate cyclase stimulator, significantly improved 6-minute walk distance in patients with inoperable...
-
From:Obesity, Fitness & Wellness WeekA report, "CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival," is newly published data in Lung. "CXC-chemokine ligand 10 (CXCL10) inhibits angiogenesis and attracts...